scholarly journals Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652

1995 ◽  
Vol 15 (5) ◽  
pp. 798-805 ◽  
Author(s):  
Zsolt Szabo ◽  
Ursula Scheffel ◽  
Makiko Suehiro ◽  
Robert F. Dannals ◽  
Sang Eun Kim ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Specific Binding ◽  
Emission Tomography ◽  
Time Interval ◽  
Papio Anubis ◽  
Primate Brain ◽  
Positron Emission ◽  
Uptake Sites ◽  
Anubis Baboons ◽  
5 Ht Uptake

[C]McN5652 is a new radioligand specific for 5-hydroxytryptamine (5-HT; serotonin) transporters. In this study we used [11C]McN5652 to image the 5-HT transporter sites in baboon brain by positron emission tomography (PET). Dynamic PET studies were performed in three Papio anubis baboons. The animals were injected intravenously first with 11C-labeled (+)-McN5652([11C](+)McN5652), then with pharmacologically inactive enantiomer 11C-labeled (–)-McN5652 ([11C](–)McN5652); two animals received a third study with [11C](+)McN5652 after pretreatment with the specific 5-HT uptake site inhibitor fluoxetine (5 mg/kg). Initial uptake into the brain was similar for both [11C](+)McN5652 and [11C](–)McN5652. At later times (45–120 min after injection), only [11C](+)McN5652 showed a distribution characteristic for 5-HT uptake sites. In contrast, in studies with [11C](–)McN5652 and in those with [11C](+)McN5652 after 5-HT uptake site blockade with fluoxetine, 11C radioactivity concentrations were significantly lower and the distribution pattern was relatively even. The differences between [11C](+)-and (–)McN5652 were calculated for the time interval 95–125 min postinjection and used to estimate specific binding. Specific binding correlated well ( r = 0.95, p < 0.001) with the known density of 5-HT uptake sites in human brain. These results indicate that [11C](+)McN5652 is suitable for PET imaging of 5-HT uptake sites in primate brain.

scholarly journals Imaging angiogenesis using 68Ga-NOTA-PRGD2 positron emission tomography/computed tomography in patients with severe intracranial atherosclerotic disease

2017 ◽  
Vol 37 (10) ◽  
pp. 3401-3408 ◽  
Author(s):  
Shi Shu ◽  
Li Zhang ◽  
Yi Cheng Zhu ◽  
Fang Li ◽  
Li Ying Cui ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Time Interval ◽  
Arterial Lesion ◽  
Event Time ◽  
Intracranial Atherosclerotic Disease ◽  
Positron Emission ◽  
Recent Group ◽  
The Brain

Angiogenesis is a critical compensation route, which has been demonstrated in the brain following ischemic stroke; however, few studies have investigated angiogenesis in chronic intracranial atherosclerosis disease (ICAD). We used 68Ga-NOTA-PRGD2 positron emission tomography/computed tomography based imaging to detect angiogenesis in chronic ICAD and to explore the factors that may have affected it. A total of 21 participants with unilateral severe chronic ICAD were included in the study. Of the 21 participants, 19 were men; the mean (SD) age was 52 (15) years. In 18 participants, we observed elevated 68Ga-NOTA-PRGD2 uptake in the peri-infarct, subcortical, and periventricular regions of the lesioned side, with a higher 68Ga-NOTA-PRGD2 SUVmax compared to that in the contralateral hemisphere (0.15 vs. 0.06, p=0.001). The 18F-FDG PET SUVmax was significantly lower on the lesioned side (11.28 vs. 13.92, p=0.001). Subgroup analyses revealed that the recent group (<6 months) had a higher lesion-to-contralateral region ratio SUVmax than the remote group (>6 months) (6.73 vs. 2.36, p<0.05). Our results provide molecular imaging evidence of angiogenesis in patients with severe chronic ICAD. Furthermore, the extent of angiogenesis in chronic ICAD may be affected by the post-qualified event time interval, and not by infarction itself or the severity of the arterial lesion.

scholarly journals A Baboon Brain Atlas for Magnetic Resonance Imaging and Positron Emission Tomography Image Analysis

2022 ◽  
Vol 15 ◽  
Author(s):  
Artur Agaronyan ◽  
Raeyan Syed ◽  
Ryan Kim ◽  
Chao-Hsiung Hsu ◽  
Scott A. Love ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Positron Emission Tomography ◽  
Magnetic Resonance ◽  
Standardized Uptake Value ◽  
Emission Tomography ◽  
Brain Atlas ◽  
Resonance Imaging ◽  
Papio Anubis ◽  
Olive Baboon ◽  
Positron Emission

The olive baboon (Papio anubis) is phylogenetically proximal to humans. Investigation into the baboon brain has shed light on the function and organization of the human brain, as well as on the mechanistic insights of neurological disorders such as Alzheimer’s and Parkinson’s. Non-invasive brain imaging, including positron emission tomography (PET) and magnetic resonance imaging (MRI), are the primary outcome measures frequently used in baboon studies. PET functional imaging has long been used to study cerebral metabolic processes, though it lacks clear and reliable anatomical information. In contrast, MRI provides a clear definition of soft tissue with high resolution and contrast to distinguish brain pathology and anatomy, but lacks specific markers of neuroreceptors and/or neurometabolites. There is a need to create a brain atlas that combines the anatomical and functional/neurochemical data independently available from MRI and PET. For this purpose, a three-dimensional atlas of the olive baboon brain was developed to enable multimodal imaging analysis. The atlas was created on a population-representative template encompassing 89 baboon brains. The atlas defines 24 brain regions, including the thalamus, cerebral cortex, putamen, corpus callosum, and insula. The atlas was evaluated with four MRI images and 20 PET images employing the radiotracers for [11C]benzamide, [11C]metergoline, [18F]FAHA, and [11C]rolipram, with and without structural aids like [18F]flurodeoxyglycose images. The atlas-based analysis pipeline includes automated segmentation, registration, quantification of region volume, the volume of distribution, and standardized uptake value. Results showed that, in comparison to PET analysis utilizing the “gold standard” manual quantification by neuroscientists, the performance of the atlas-based analysis was at &gt;80 and &gt;70% agreement for MRI and PET, respectively. The atlas can serve as a foundation for further refinement, and incorporation into a high-throughput workflow of baboon PET and MRI data. The new atlas is freely available on the Figshare online repository (https://doi.org/10.6084/m9.figshare.16663339), and the template images are available from neuroImaging tools &amp; resources collaboratory (NITRC) (https://www.nitrc.org/projects/haiko89/).

scholarly journals Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies

1998 ◽  
Vol 18 (10) ◽  
pp. 1130-1142 ◽  
Author(s):  
Richard E. Carson ◽  
Dale O. Kiesewetter ◽  
Elaine Jagoda ◽  
Margaret G. Der ◽  
Peter Herscovitch ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Basal Ganglia ◽  
Specific Binding ◽  
Emission Tomography ◽  
Ache Inhibitor ◽  
Parameter Estimates ◽  
Tracer Injection ◽  
Positron Emission ◽  
Muscarinic Cholinergic

[18F]Fluoropropyl-TZTP (FP-TZTP) is a subtype-selective muscarinic cholinergic ligand with potential suitability for studying Alzheimer's disease. Positron emission tomography studies in isofluorane-anesthetized rhesus monkeys were performed to assess the in vivo behavior of this radiotracer. First, control studies (n = 11) were performed to characterize the tracer kinetics and to choose an appropriate model using a metabolite-corrected arterial input function. Second, preblocking studies (n = 4) with unlabeled FP-TZTP were used to measure nonspecific binding. Third, the sensitivity of [18F]FP-TZTP binding to changes in brain acetylcholine (ACh) was assessed by administering physostigmine, an acetylcholinesterase (AChE) inhibitor, by intravenous infusion (100 to 200 μg·kg−1·h−1) beginning 30 minutes before tracer injection (n = 7). Tracer uptake in the brain was rapid with K1 values of 0.4 to 0.6 mL·min−1·mL−1 in gray matter. A model with one tissue compartment was chosen because reliable parameter estimates could not be obtained with a more complex model. Volume of distribution ( V) values, determined from functional images created by pixel-by-pixel fitting, were very similar in cortical regions, basal ganglia, and thalamus, but significantly lower ( P < 0.01) in the cerebellum, consistent with the distribution of M2 cholinergic receptors. Preblocking studies with unlabeled FP-TZTP reduced V by 60% to 70% in cortical and subcortical regions. Physostigmine produced a 35% reduction in cortical specific binding ( P < 0.05), consistent with increased ACh competition. The reduction in basal ganglia (12%) was significantly smaller ( P < 0.05), consistent with its markedly higher AChE activity. These studies indicate that [18F]FP-TZTP should be useful for the in vivo measurement of muscarinic receptors with positron emission tomography.

scholarly journals Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [18F]-FEPPA and Positron Emission Tomography

2011 ◽  
Vol 31 (8) ◽  
pp. 1807-1816 ◽  
Author(s):  
Pablo M Rusjan ◽  
Alan A Wilson ◽  
Peter M Bloomfield ◽  
Irina Vitcu ◽  
Jeffrey H Meyer ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Human Brain ◽  
Specific Binding ◽  
Compartment Model ◽  
Distribution Volume ◽  
Translocator Protein ◽  
Emission Tomography ◽  
Binding Potential ◽  
Specific Distribution ◽  
Positron Emission

This article describes the kinetic modeling of [18F]-FEPPA binding to translocator protein 18 kDa in the human brain using high-resolution research tomograph (HRRT) positron emission tomography. Positron emission tomography scans were performed in 12 healthy volunteers for 180 minutes. A two-tissue compartment model (2-CM) provided, with no exception, better fits to the data than a one-tissue model. Estimates of total distribution volume ( VT), specific distribution volume ( VS), and binding potential ( BPND) demonstrated very good identifiability (based on coefficient of variation ( COV)) for all the regions of interest (ROIs) in the gray matter ( COV VT < 7%, COV VS < 8%, COV BPND < 11%). Reduction of the length of the scan to 2 hours is feasible as VS and VT showed only a small bias (6% and 7.5%, respectively). Monte Carlo simulations showed that, even under conditions of a 500% increase in specific binding, the identifiability of VT and VS was still very good with COV<10%, across high-uptake ROIs. The excellent identifiability of VT values obtained from an unconstrained 2-CM with data from a 2-hour scan support the use of VT as an appropriate and feasible outcome measure for [18F]-FEPPA.

scholarly journals Comparison of [11C]Diprenorphine and [11C]Carfentanil Binding to Opiate Receptors in Humans by Positron Emission Tomography

1990 ◽  
Vol 10 (4) ◽  
pp. 484-492 ◽  
Author(s):  
J. James Frost ◽  
Helen S. Mayberg ◽  
Bernard Sadzot ◽  
Robert F. Dannals ◽  
John R. Lever ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Specific Binding ◽  
Regional Distribution ◽  
Opiate Receptors ◽  
Opiate Receptor ◽  
Total Radioactivity ◽  
Emission Tomography ◽  
Receptor Subtypes ◽  
Positron Emission ◽  
Kinetics Of

The kinetics and regional distribution of [11C]carfentanil, a μ-selective opiate receptor agonist, and [11C]diprenorphine, a nonselective opiate receptor antagonist, were compared using paired positron emission tomography studies in two normal volunteers. Kinetics of total radioactivity (counts/mCi/pixel) was greater for [11C]diprenorphine than [11C]carfentanil in all regions. [11C]Carfentanil binding (expressed as the total/nonspecific ratio) reached near equilibrium at ∼40 min, whereas [11C]diprenorphine showed a linear increase until ∼60 min. Kinetics of specific binding demonstrated significant dissociation of [11C]carfentanil from opiate receptors, whereas little dissociation of [11C]diprenorphine was observed during the 90-min scan session. Regional distributions of [11C]carfentanil and [11C]diprenorphine were qualitatively and quantitatively different: Relative to the thalamus (a region with known predominance of μ-receptors), [11C]diprenorphine displayed greater binding in the striatum and cingulate and frontal cortex compared to [11C]carfentanil, consistent with labeling of additional, non-μ sites by [11C]diprenorphine. We conclude from these studies that [11C]diprenorphine labels other opiate receptor subtypes in addition to the μ sites selectively labeled by [11C]carfentanil. The nonselective nature of diprenorphine potentially limits its usefulness in defining abnormalities of specific opiate receptor subtypes in various diseases. Development of selective tracers for the δ- and κ-opiate receptor sites, or alternatively use of unlabeled inhibitors to differentially displace μ, δ, and κ subtypes, will help offset these limitations.

[11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain

NeuroImage ◽  
2008 ◽  
Vol 41 (3) ◽  
pp. 1075-1085 ◽  
Author(s):  
M. Edward Pierson ◽  
Jan Andersson ◽  
Svante Nyberg ◽  
Dennis J. McCarthy ◽  
Sjoerd J. Finnema ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Primate Brain ◽  
Positron Emission

Brain kinetics and specific binding of [11C]PK 11195 to ω3 sites in baboons: positron emission tomography study

1991 ◽  
Vol 200 (2-3) ◽  
pp. 347-351 ◽  
Author(s):  
Marie-Christine Petit-Taboué ◽  
Jean-Claude Baron ◽  
Louisa Barré ◽  
Jean-Marcel Travère ◽  
Daniel Speckel ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Specific Binding ◽  
Emission Tomography ◽  
Positron Emission Tomography Study ◽  
Positron Emission

Carbon-11 pb-12: an attempt to visualize the dopamine d4 receptor in the primate brain with positron emission tomography

2000 ◽  
Vol 27 (8) ◽  
pp. 707-714 ◽  
Author(s):  
Oliver Langer ◽  
Christer Halldin ◽  
Yuan-Hwa Chou ◽  
Johan Sandell ◽  
Carl-Gunnar Swahn ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Dopamine D4 Receptor ◽  
Primate Brain ◽  
Positron Emission ◽  
D4 Receptor

scholarly journals The Use of Spectral Analysis to Determine Regional Cerebral Glucose Utilization with Positron Emission Tomography and [18F]Fluorodeoxyglucose: Theory, Implementation, and Optimization Procedures

1994 ◽  
Vol 14 (3) ◽  
pp. 406-422 ◽  
Author(s):  
F. Turkheimer ◽  
R. M. Moresco ◽  
G. Lucignani ◽  
L. Sokoloff ◽  
F. Fazio ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Spectral Analysis ◽  
Kinetic Analysis ◽  
Glucose Utilization ◽  
Emission Tomography ◽  
Small Subset ◽  
Time Interval ◽  
Kinetic Properties ◽  
Cerebral Glucose Utilization ◽  
Positron Emission

A method for kinetic analysis of dynamic positron emission tomography (PET) data by linear programming that allows identification of the components of a measured PET signal without predefining a compartmental model has recently been proposed by Cunningham and co-workers. The method identifies a small subset of functions from a large input set of feasible functions that best fits the time course of total radioactivity measured by PET. To investigate in detail the properties of this technique, we applied it to PET studies with [18F]fluorodeoxyglucose, a tracer with well-characterized kinetic properties. We examined dynamically acquired data over various time intervals in many brain regions and found that the number of components identified by the method is stable and consistent with the presence of kinetic heterogeneity in every region. We optimized the method for determination of regional rates of glucose utilization; calculated rates were found to be somewhat dependent upon the treatment of noise in the measured tissue data and upon the time interval in which the data were collected. The application of a numerical filter to remove noise in the data resulted in values for regional cerebral glucose utilization that were stable with time and consistent with rates determined by the other established techniques. Based on the results of the current study, we expect that the spectral analysis technique will prove to be a highly flexible tool for kinetic analysis of other tracer compounds; it is capable of producing low-variance, time-stable estimates of physiological parameters when optimized for time interval of application, input spectrum of components, and processing of noise in the data.

Sign in / Sign up

Export Citation Format

Share Document